EN DE
Watch Zhongzhu Medical Holdings Co Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Zhongzhu Medical Holdings Co Ltd (600568) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Zhongzhu Medical Holdings Co Ltd stock ¥0.35, price ¥2.10, that is 83.3% below the price, quality 59 out of 100. Rating: strongly overvalued. Calculated from audited financials with 7 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN · ISIN CNE0000017X8

ZM Zhongzhu Medical Holdings Co Ltd logo Thin data Nov 7, 2026

Zhongzhu Medical Holdings Co Ltd

600568 · SHG
Solid, but very expensive

Our calculation puts a fair price 83% below what the stock costs today.

Low debt
Quality 59/100
Fair value ¥0.3500 · Strongly overvalued
Weak Growth (revenue 5y −4.5 %/yr in CNY)
Loss-making · -24.8% net margin (TTM)
Negative free cash flow over the last twelve months
Trails peers (2/11)
Narrow moat 12/100 · thin data
Thin data
Watch Zhongzhu Medical Holdings Co Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥3.21 ¥1.13 Fair Value ¥0.3500 May 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

60‑month range ¥1.13 – ¥3.21 · fair‑value band ¥0.3100 – ¥0.4100 · the ¥2.10 price screens above the ¥0.3500 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 7, 2026.

Follow Zhongzhu Medical Holdings Co in your weekly email

Every Wednesday you see whether Zhongzhu Medical Holdings Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Zhongzhu Healthcare Holding Co.,Ltd engages in the research and development, production, and sale of drugs in China.

Show moreShow less

The company offers ophthalmology drugs, including Pearl eye drops, Sodium Cromolyn eye drops, Acyclovir eye drops, Hydroxybenzone Hydrochloride eye drops, Acyclovir dispersible tablets, and Gatifloxacin tablets; and products related to tumor treatment.

It is also involved in production and sales of products of hepatest ultrasonic liver cirrhosis detector, infusion heater, and Moon God whole body gamma knife.

In addition, the company develops 1.1-class chemical drug Leonurine (SCM-198) project with the effect of lowering blood lipids and preventing and treating stroke; and genistein capsules for the treatment of osteoporosis.

Further, it engages in residential real estate development; business management; hospital investment management; technology promotion and application services; research and experimental development; special equipment manufacturing industry; and financial leasing business.

Zhongzhu Healthcare Holding Co.,Ltd was formerly known as Zhongzhu Holding Co., Ltd. and changed its name to Zhongzhu Healthcare Holding Co., Ltd in June 2016. The company was founded in 1970 and is headquartered in Zhuhai, China.

Stock analysis

Zhongzhu Medical Holdings Co Ltd (600568) currently trades at ¥2.10, while our model-based Fair Value estimate is ¥0.3500, 83% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of ¥0.3900 per share, and 0 of the 7 models we run sit above the ¥2.10 price.

Bear case: the DCF Models group reads lowest at ¥0.3500, and 7 of the 7 models stay below the price. Data coverage for this calculation is low.

Scenario range: ¥0.3100 (bear) to ¥0.4100 (bull), the price of ¥2.10 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Zhongzhu Medical Holdings Co Ltd reported revenue of 577M CNY in FY2025 versus 581M CNY in FY2021, a compound −0.2%/yr. Reported net income was −114M CNY in FY2025.

Key figures

Market cap 4.2B CNY (≈ $627M) Small · P/S ratio 7.76 · EPS (TTM) ¥−0.0700 · Net margin −24.8% · Return on equity −8.3% · Return on assets (EBIT) −13.8% (5-year average) · Operating margin −15.7% · Revenue (TTM) 534M CNY.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

The share trades about 35% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −83%, 600568 screens richer than that median.

Fair Value models

Bear ¥0.3100 Fair Value ¥0.3500 Bull ¥0.4100
Price ¥2.10 · Downside -83.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF ¥0.3000 ¥0.3600 ¥0.4200 82
Growth DCF ¥0.3100 ¥0.3500 ¥0.4100 80
5Y Revenue Exit ¥0.3000 ¥0.3500 ¥0.4200 74
All 7 models by family
DCF Models
FCF DCF ¥0.3000 ¥0.3600 ¥0.4200 82
5Y Revenue Exit ¥0.3000 ¥0.3500 ¥0.4200 74
10Y Revenue Exit ¥0.3000 ¥0.3500 ¥0.4100 68
Multiples
EV/Revenue ¥0.3100 ¥0.3500 ¥0.4000 54
Asset-Based
NCAV (Graham) ¥0.2600 ¥0.3900 ¥0.4900 54
Growth DCF
Growth DCF ¥0.3100 ¥0.3500 ¥0.4100 80
Rev-Margin DCF ¥0.3000 ¥0.3500 ¥0.4200 74

Open the full fair value analysis →

Quality Score breakdown

Overall quality 59/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 4
How much profit the company makes from its sales and capital
Quality Growth 85
Are margins and returns getting better?
Cashflow 29
Do the profits arrive as real cash?
Financial strength 91
Debt, balance sheet and risk of trouble
Investment 93
Does it invest with discipline instead of growing at any price?
Low Volatility 73
How calm the share price moves, does not count
Price momentum 32
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 25
Distance to the 52-week high, does not count
New shares 76
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 24/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+10.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.5%
Start year 2020 (pandemic). Over 10 years: −4.6% a year
Revenue growth 27 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
6.4% (2020) → −10.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+53.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +51.0% a year for the price.

600568 screens overvalued: fair value 83% below the price. Compare with Merck KGaA →

Compare Zhongzhu Medical Holdings Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks

Beats the industry median on 2/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 59 · Above median
Fair Value upside −83.3% · Bottom 25%
Profitability
Return on assets −5.8% · Bottom 25%
Net margin (12 months) −24.8% · Bottom 25%
Operating margin (12 months) −15.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −6.7% · Below median
Balance sheet
Debt / equity 0.01× · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 2.56× · Pricier than median
P/S (12 months) 7.84× · Priciest 25%
Price / free cash flow (fiscal year) 174.4× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 15
FUTURE (revenue growth)0 · sector 25
PAST (return on equity)0 · sector 29
HEALTH (low debt)99 · sector 96
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $113.53 +43% vs 600568
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.43 ¥55.21 +9% vs 600568
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,860 ₹1,947 +5% vs 600568
Haleon plc HLN $9.14 $8.61 −6% vs 600568
Merck KGaA MRK €148.75 €109.18 −27% vs 600568
Galderma Group GALD CHF 191.75 CHF 109.86 −43% vs 600568
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs 600568
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs 600568
Sandoz Group SDZ CHF 83.78 CHF 39.70 −53% vs 600568
Divi's Laboratories Limited DIVISLAB ₹10,321 ₹1,567 −85% vs 600568

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Zhongzhu Medical Holdings Co Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Zhongzhu Medical Holdings Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/600568

Frequently asked questions

Is Zhongzhu Medical Holdings Co Ltd (600568) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of ¥0.3500 versus a price of ¥2.10, about 83% lower (overvalued).
What is the fair value of 600568?
Our model-based fair value for Zhongzhu Medical Holdings Co Ltd is ¥0.3500 (as of Nov 7, 2026), built from audited fundamentals. The current price: ¥2.10.
What is the quality score of 600568?
Zhongzhu Medical Holdings Co Ltd has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Zhongzhu Medical Holdings Co Ltd (600568)?
Our model-based price target is the fair value of ¥0.3500 (as of Nov 7, 2026) from 7 valuation models. Cautious scenario ¥0.3100, optimistic scenario ¥0.4100. It is a calculation from audited fundamentals, not an analyst target.
What is the Zhongzhu Medical Holdings Co Ltd stock forecast for 2026?
Our models put fair value at ¥0.3500, about 83% lower versus a price of ¥2.10 (overvalued). Cautious scenario ¥0.3100, optimistic scenario ¥0.4100. The calculation is refreshed regularly with new filings.
What is the revenue of Zhongzhu Medical Holdings Co Ltd (600568)?
Zhongzhu Medical Holdings Co Ltd reported trailing-twelve-month revenue of about 534M CNY (latest available figure, as of Nov 7, 2026).
What growth is priced into Zhongzhu Medical Holdings Co Ltd (600568)?
For today's price to be fair in a discounted-cash-flow model, Zhongzhu Medical Holdings Co Ltd would have to grow free cash flow by +53.5 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -4.5 % per year. Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of 600568 use?
Our models discount Zhongzhu Medical Holdings Co Ltd at 10.4 %: a base by market capitalisation (small), damped by beta 0.14, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Zhongzhu Medical Holdings Co Ltd that is +53.5 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has Zhongzhu Medical Holdings Co Ltd (600568) delivered so far?
Over the past 5 years revenue at Zhongzhu Medical Holdings Co Ltd grew -4.5 % a year. The price currently implies free-cash-flow growth of +53.5 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Zhongzhu Medical Holdings Co Ltd (600568) growing?
The median revenue growth in the sector is +2.7 % a year. That is the yardstick for the growth priced into Zhongzhu Medical Holdings Co Ltd (+53.5 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Zhongzhu Medical Holdings Co Ltd (600568)?
The free-cash-flow yield on the price is 0.57 % in the last fiscal year (free cash flow was negative over the last twelve months): that much free cash flow Zhongzhu Medical Holdings Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Zhongzhu Medical Holdings Co Ltd (600568)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Zhongzhu Medical Holdings Co Ltd it is ¥0.3500 per share (as of Nov 7, 2026), against a price of ¥2.10. It is the blended result of 7 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is Zhongzhu Medical Holdings Co Ltd stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 600568 trades above its calculated fair value: price ¥2.10, fair value ¥0.3500, a gap of about −83% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 600568?
No. The price is what the market pays today (¥2.10); the fair value is what the company's own numbers justify (¥0.3500). For Zhongzhu Medical Holdings Co Ltd the two are ¥1.75 per share apart. That gap is exactly why we show both numbers side by side.
How much is Zhongzhu Medical Holdings Co Ltd worth?
The market values Zhongzhu Medical Holdings Co Ltd at about 4.2B CNY (market capitalisation, as of Nov 7, 2026). Per share that is ¥2.10; our models calculate a fair value of ¥0.3500 per share.
What do the bullish and bearish scenarios say about 600568?
Our models span a range for Zhongzhu Medical Holdings Co Ltd: cautious scenario ¥0.3100, base ¥0.3500, optimistic ¥0.4100 per share (as of Nov 7, 2026, price ¥2.10). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Zhongzhu Medical Holdings Co Ltd (600568)?
Balance-sheet figures for Zhongzhu Medical Holdings Co Ltd (as of Nov 7, 2026): return on equity −8.3%, debt of 0.01 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is 600568 from its 52-week high?
Zhongzhu Medical Holdings Co Ltd trades at ¥2.10, about 35% below its 52-week high of ¥3.21 and 8% above the low of ¥1.94 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥0.3500 is for.
Which stocks are comparable to Zhongzhu Medical Holdings Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Zhongzhu Medical Holdings Co Ltd stock attractive at the current price?
The data as of Nov 7, 2026: price ¥2.10, calculated fair value ¥0.3500 (−83%), Quality Score 59/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 600568 calculated?
We run Zhongzhu Medical Holdings Co Ltd through 7 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of ¥0.3500 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Zhongzhu Medical Holdings Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Zhongzhu Medical Holdings Co Ltd (600568)?
The closing price on Nov 6, 2026 was ¥2.10. Our model-based fair value is ¥0.3500, about 83% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Zhongzhu Medical Holdings Co Ltd right now?
The price sits above even our optimistic bull case (¥0.4100). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Zhongzhu Medical Holdings Co Ltd

How large is the market capitalisation of Zhongzhu Medical Holdings Co Ltd (600568)?
The market capitalisation of Zhongzhu Medical Holdings Co Ltd is 4.2B CNY (≈ $627M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Zhongzhu Medical Holdings Co Ltd (600568)?
The price-to-sales ratio of Zhongzhu Medical Holdings Co Ltd is 7.76 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Zhongzhu Medical Holdings Co Ltd (600568)?
Earnings per share at Zhongzhu Medical Holdings Co Ltd are ¥−0.0700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Zhongzhu Medical Holdings Co Ltd (600568)?
The net margin of Zhongzhu Medical Holdings Co Ltd is −24.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Zhongzhu Medical Holdings Co Ltd (600568)?
The return on equity (ROE) of Zhongzhu Medical Holdings Co Ltd is −8.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Zhongzhu Medical Holdings Co Ltd (600568)?
On an EBIT basis the return on assets of Zhongzhu Medical Holdings Co Ltd is −13.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Zhongzhu Medical Holdings Co Ltd (600568)?
The operating margin of Zhongzhu Medical Holdings Co Ltd is −15.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Zhongzhu Medical Holdings Co Ltd (600568)?
Revenue at Zhongzhu Medical Holdings Co Ltd is growing −6.7% versus a year earlier (3y avg +4.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net cash does Zhongzhu Medical Holdings Co Ltd (600568) hold?
Zhongzhu Medical Holdings Co Ltd holds more cash than debt, 392M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Zhongzhu Medical Holdings Co Ltd in the live analysis

One click puts Zhongzhu Medical Holdings Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.